Citations

Institution: Mayo Clinic Clear

Showing 10 of 108083 citations.

Deep Learning for Decision Support in Ovarian Cancer Treatment Planning
Fati, Francesca, Rosanu, Marina , Vitis, Luigi Antonio De , Rota, Alberto , Ribero, Lucia , Colombo, Nicoletta , Peiretti, Michele , Veraldi, Roberto , Spadea, Maria Francesca , Momi, Elena De, Momi, Elena De , Traversa, Alice , Schivardi, Gabriella , Petralia, Giuseppe , Aletti, Giovanni , Angioni, Stefano , Casarin, Jvan , Veraldi, Roberto, Zaffino, Paolo , Multinu, Francesco

No container title available | September 17, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7434368/v1 Get It

Abstract Ovarian cancer is the deadliest gynecologic malignancy worldwide, with a 5-year overall survival rate of approximately 49%. Although complete resection is associated with the most favorable prognosis following primary debulking surgery, accurately assessing tumor resectability at diagnosis remains a major clinical challenge. We propose a decision support system (DSS) designed to predict residual tumor after primary debulking surgery, based on clinical and imaging data available at diagnosis. The system was developed and validated using a retrospective cohort of 465 patients with high-grade serous ovarian cancer, collected at the European Institute of Oncology in Milan, Italy. We developed a deep learning (DL) model that combines pre-trained Vision Transformer encoders with an attention mechanism and a classification head. When evaluated on an independent test cohort of 75 cases, our best-performing model achieved an area under the curve (AUC) of 0.80 (95% CI: 0.68–0.89) and a recall of 0.86 (95% CI: 0.71–0.97), demonstrating discriminatory ability with a particularly low rate of false negatives. Clinically, the model correctly identified 24 out of 28 patients (86%) with non-resectable disease, who would not have benefited from primary debulking surgery. Notably, within this subgroup, the model accurately predicted 93% (13 out of 14) of cases in which surgery was aborted intraoperatively due to unforeseen unresectable disease. These findings suggest that the model could have potential in preventing unnecessary and inappropriate surgical interventions. The proposed DSS is a fully automated, DL–based system for predicting tumor resectability at diagnosis, without the need for manual segmentation or expert evaluation of radiological features and structured clinical parameters. This approach could facilitate and accelerate personalized treatment planning in ovarian cancer. The work is part of the project Under-XAI: understanding ovarian cancer initiation and progression through explainable AI. Project code: PNRR-MAD-2022-12376574.
Unique Immune Polarization of the Lung Allograft: Implications for Organ-specific Immunoregulation and Tolerance Induction
Leyder, Erica , Taheri, Mojtaba , Neschis, Michael , Jacobsen, Elizabeth A. , Kreisel, Daniel , Krupnick, Alexander S. , Mei, Zhongcheng , Jacobsen, Elizabeth A , Banerjee, Anirban M. , Gelman, Andrew E

Transplantation | September 17, 2025 | Volume: 110 | Issue: 2 | Pages: e324-e332

10.1097/tp.0000000000005521 | PMID 40958148 Get It

Technological innovations have improved many barriers in lung transplantation, but high rates of acute and chronic rejection still limit lung allograft survival. This may be explained by the unique environment of the lung. As a mucosal barrier organ, the lung is constantly exposed to the external environment, leading to unique immunological features that are not seen in other transplantable solid organ allografts such as hearts, kidneys, and livers. Thus, the higher rates of rejection and poor long-term survival of lung transplant recipients may stem from the global immunosuppression strategies that are indiscriminately used for all solid organ grafts. Data from our laboratory, and others, have demonstrated that the unique immunoregulatory pathways of the lung may require different strategies for long-term graft survival. For example, depletion of CD8 + T cells typically contributes to the acceptance of transplanted organs. However, these cells facilitate lung allograft acceptance through interferon gamma mediated nitric oxide production. Interestingly CD8 + T cells modify and polarize eosinophils to produce nitric oxide as a means of tolerance induction. Such eosinophils also function to maintain long-term lung allograft acceptance by interfering with humoral alloimmunity. For most other organs eosinophils are suspected to contribute to graft rejection. In this review, we aim to describe the cytokine pathways involved in lung allograft rejection or tolerance, contrast such pathways to those evident in other solid organs, and discuss the need for further studies that can be used to design rational methods for altering the cytokine environment to improve lung allograft survival.
Catheter Ablation for Ventricular Tachycardia in Ischemic Cardiomyopathy: A Meta‐Analysis With Reconstructed Time‐to‐Event and Trial Sequential Analysis
Elbenawi, Hossam , Ayman, Youmna , Hashim, Ahmed , Wagdy, Mohamed, Thakurathi, Priyesh , Al‐Shammari, Ali Saad , Mohamed, Kareem A., Kalaiger, Abdul M., Ibrahim, Ahmed M. , Eisa, Mahmoud , Ibrahim, Ramzi , Zaaya, Morad, Almaadawy, Omar , Quelal, Karol , Lee, Justin Z. , Siontis, Konstantinos C. , Munoz, Freddy Del‐Carpio , Deshmukh, Abhishek , Agarwal, Siddharth , Al-Shammari, Ali Saad , Ibrahim, Ramzi , Tan, Min Choon , Quelal, Karol , Asad, Zain Ul Abideen , Siontis, Konstantinos C , Del-Carpio Munoz, Freddy , DeSimone, Christopher V , Deshmukh, Abhishek J , Agarwal, Siddharth , Kalaiger, Abdul Mukhtadir , Agarwal, Siddharth, Wagdy, Mohamed , Hamed, Belal Mohamed , Mohamed, Kareem A., Ibrahim, Ramzi , Asad, Zain Ul Abideen , Arenal, Ángel , DeSimone, Christopher V.

Journal of Cardiovascular Electrophysiology | September 17, 2025 | Volume: 36 | Issue: 11 | Pages: 2934-2949

10.1111/jce.70075 | PMID 40958137 Get It

ABSTRACT Background Ventricular tachycardia (VT) is a major contributor to sudden cardiac death among patients with ischemic heart disease (IHD). While catheter ablation reduces the arrhythmic burden, the impact on long‐term outcomes remains uncertain. We assess the efficacy of catheter ablation in patients with IHD. Methods We performed a meta‐analysis by systematically searching electronic databases from inception to April 2025. Pairwise, reconstructed time‐to‐event data meta‐analyses and Trial Sequential analyses were conducted. Results A total of seven studies (1192 participants) were included. Among patients with IHD with ICD, VT ablation was associated with a significant reduction in ICD shocks (RR = 0.50, 95% CI = [0.34–0.74]), a trend toward reduced VT storm (RR = 0.64, 95% CI = [0.40–1.04], p = 0.07), and lower rates of cardiovascular hospitalization (RR = 0.73, 95% CI = [0.53–1.01], p = 0.06) compared to ICD alone. However, no significant differences were observed when compared to patients receiving ICD plus antiarrhythmic drugs (AADs). VT ablation showed no significant impact on mortality or VT/VF recurrence compared to either ICD alone or ICD with AADs. Reconstructed Kaplan–Meier analysis for all‐cause mortality showed no significant difference between VT ablation and AAD + ICD. Trial Sequential Analysis provided conclusive evidence for VT/VF recurrence, while further data is required for other outcomes. Conclusion Among patients with IHD with ICD, VT ablation reduces ICD shocks, VT storm, and cardiovascular hospitalizations compared to ICD‐only therapy, but offers no significant advantage over ICD combined with AADs. VT ablation does not impact overall mortality or the recurrence of VT/VF. Trial sequential analysis confirmed conclusive evidence for VT/VF recurrence, while additional data is needed for other outcomes.
Computer-based Auditory Training in New Adult Cochlear Implant Recipients: A Review of Training Outcomes in More than 100 Patients in the Outpatient Setting
Dornhoffer, James R. , Schvartz‐Leyzac, Kara C. , Dubno, Judy R. , McRackan, Theodore R.

Seminars in Hearing | September 16, 2025 | Volume: 46 | Issue: 02 | Pages: 107-124

10.1055/s-0045-1811560 | PMID 41036262 Get It

AbstractTo review research on the effectiveness of computer-based auditory training (CBAT) in new adult cochlear implant (CI) recipients.Studies by the primary author on auditory training in new adult CI recipients were reviewed, focusing on a database of auditory training data in >100 patients followed over their first-year post-activation.CBAT, as used in a standard outpatient setting, affords benefits compared to other commonly employed exercises/programs. In new adult CI users, CBAT was associated with greater improvement in CNC words, AzBio sentences, and Cochlear Implant Quality of Life-35 (CIQOL-35) Profile scores at 3 months post-activation compared to CI recipients who did not train or used other resources. By 12 months, patients showed similar improvement in speech recognition scores, regardless of training modality; however, patients who used CBAT continued to show significantly greater improvement in CIQOL global and all domain scores compared to CBAT nonusers. This benefit was noted regardless of whether CBAT was started before or after 3 months post-activation. No demographic/lifestyle factors, audiological measures, or pre-CI CIQOL/CIQOL-Expectations scores were associated with CBAT use.CBAT during the first-year post-activation may contribute to early gains in CI speech recognition and to persistent improvements in functional abilities, as measured via the CIQOL-35 profile, in new implant recipients. Consideration of specific recommendations for the use of CBAT resources may be valuable, given the minimal risk, ease of access, and affordability of these programs.
Documentation of menopause-related international classification of diseases codes in the electronic health record in midlife women with menopause symptoms
Karam, J H, Safwan, Nancy , Pevnick, Joshua M. , Berdahl, Carl T. , Chaudhry, Rajeev , Kapoor, Ekta , Cole, Kristin , Shufelt, Chrisandra , Shufelt, Chrisandra L , Karam, Jana, Carter, Rickey E. , Chaudhry, Rajeev, Kling, Juliana M. , Winham, Stacey J. , Faubion, Stephanie S.

Menopause | September 16, 2025 | Volume: 33 | Issue: 3 | Pages: 290-296

10.1097/gme.0000000000002648 | PMID 40957022 Get It

Objective: To evaluate the documentation of menopause-related International Classification of Diseases-10 (ICD-10) codes in the electronic health record (EHR) among midlife women with moderate or greater menopause symptoms receiving primary care. Methods: This cross-sectional study from the Hormones and Experiences of Aging (HERA) cohort included women aged 45-60 years receiving primary care at one of 4 Mayo Clinic sites who completed a one-time survey between March 1, 2021 and June 30, 2021. The survey captured demographic data, menopause symptoms using the Menopause Rating Scale (MRS), health care utilization, and treatment. Women with an MRS score ≥12 were included. The primary outcome was documentation of a menopause-related ICD-10 code in the EHR in the 12 months before survey completion. Results: Of 5,254 women with completed surveys, 2,414 (49%) had an MRS score ≥12 and were included. Among these, 1,519 (63%) reported seeking care for their menopause symptoms in the past 12 months, but only 345 (23%) had a menopause-related ICD-10 code. Women with an ICD-10 code had higher MRS scores (18 [IQR: 14-22] vs 17 [IQR: 14-20]; P = 0.002) and were more likely to use systemic hormone therapy (HT; 26% vs 9%; P < 0.001), and vaginal HT (20% vs 6%; P < 0.001). Conclusions: Menopause-related ICD-10 diagnosis codes were under-documented in women with significant menopause symptom burden. Those with a code were more likely to report menopause treatment. These findings highlight a critical gap between symptom burden and diagnosis coding in the EHR, underscoring the need to improve identification and management of menopause symptoms.
Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP)
Tsung, Irene , Smith, David C. , Heath, Elisabeth I. , Cackowski, Frank C. , Devitt, Michael , Braun, Thomas , Yentz, Sarah , Nguyen, Charles B. , Shah, Neel , Vaishampayan, Ulka N. , Caram, Megan E.V. , Palmbos, Phillip L. , Alumkal, Joshi J. , Reichert, Zachery R. , Cackowski, Frank C , Devitt, Michael E , Braun, Thomas M , Dean, Emma , Vaishampayan, Ulka , Caram, Megan E V , Palmbos, Phillip , Alumkal, Joshi J , Reichert, Zachery R , Chinnaiyan, Arul , Smith, Simon A.

JCO Precision Oncology | September 16, 2025 | Volume: No volume available | Issue: 9 | Pages: No page available

10.1200/po-25-00457 | PMID 40956994 Get It

PURPOSE Preclinical studies suggest the combination of the poly(adenosine diphosphate[ADP]-ribose) polymerase (PARP) inhibitor olaparib and the ataxia telangiectasia–mutated and Rad3-related (ATR) inhibitor ceralasertib has synergistic antitumor activity in homologous recombination proficient (HRP) and homologous recombination repair gene mutation (HRRm) patients. This study aims to determine the efficacy of olaparib plus ceralasertib in metastatic castration-resistant prostate cancer (mCRPC) with and without HRRm. PATIENTS AND METHODS Thirty-five HRP and 12 HRRm PARP inhibitor–naïve patients with mCRPC progressing on ≥1 line of therapy or previous androgen receptor pathway inhibitor were enrolled. Patients received olaparib (300 mg twice daily) and ceralasertib (160 mg once daily, days 1-7) in 28-day cycles. HRRm was defined as biallelic inactivation of BRCA2 or BRCA1 , monoallelic inactivation of ATM , or germline inactivation of any of these genes. The primary end point was disease response rate (dRR; confirmed prostate-specific antigen decline ≥50% and/or complete/partial radiographic response by RECIST v1.1) in HRP patients. Secondary end points included dRR in HRRm patients, progression-free survival (PFS), and safety/toxicity. Two-stage designs were used. RESULTS Four of 35 (11%; 95% CI, 3.2 to 26.7) HRP and four of 12 HRRm patients responded. Median PFS was 8.2 months (95% CI, 5.3 to not reached) for HRP patients. Thirty-six percent of patients had ≥grade 3 toxicity, most commonly from anemia. Limitations include small, single-arm, nonrandomized trial design. CONCLUSION Combining ceralasertib with olaparib had limited activity in patients with HRP mCRPC. HRRm response rate was not greater than previous single-agent PARP inhibitor clinical trials.
Hip Pain In A Weightlifter
Lowell, Luke, Hodges, Blake, Janitz, Tyler, Nadwodny, Jeff, Schmitz, Tyler, Hodges, Blake, Pujalte, George G.A. , Schmitz, Tyler

Medicine & Science in Sports & Exercise | September 16, 2025 | Volume: 57 | Issue: 10S | Pages: 289-289

10.1249/01.mss.0001157092.36976.ca Get It

Twenty Year Performance Trends In The Arrowhead 135 Winter Ultra-Endurance Race
Wehmanen, Kyle W., Ruby, Brent C. , McDaniel, John , Elmer, Steven J. , Wehmanen, Kyle W., Petushek, Erich J. , Kipp, Shalaya

Medicine & Science in Sports & Exercise | September 16, 2025 | Volume: 57 | Issue: 10S | Pages: 794-794

10.1249/01.mss.0001161768.26093.7f Get It

Effect Of Exercise Training On Intermuscular Adipose Tissue And Insulin Resistance In Young And Older Adults
Alexander, Andrew M. , Fitzgibbons, Lucy M., Bergan, Natalie, Senefeld, Jonathon W. , Lanza, Ian R.

Medicine & Science in Sports & Exercise | September 16, 2025 | Volume: 57 | Issue: 10S | Pages: 774-775

10.1249/01.mss.0001161584.71826.f6 Get It

Resting Metabolic Rate In Collegiate Male Wrestlers: Cross-validation Of Prediction Equations
Dobbs, Ward C. , Missall, Micah, Albee, Grace, Streveler, Jonah, Twohey, Eric , Horswill, Craig A. , Fields, Jennifer , Jones, Margaret T. , Jagim, Andrew R. , Fields, Jennifer

Medicine & Science in Sports & Exercise | September 16, 2025 | Volume: 57 | Issue: 10S | Pages: 321-321

10.1249/01.mss.0001157368.50135.fa Get It